Fate Therapeutics Inc (FATE)

Number of records: 50
SEC FilingInsiderCompanyTrade DateTransactionSharesAvg. PriceTotal% HoldingsReturn
05-Mar-24 4:24 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 04-Mar-24Sale (Planned) 2,447$7.77$19,013.20(2%)
103.93K to 101.48K
30-Jan-24 4:01 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 29-Jan-24Sale (Planned) 1,849$5.00$9,245.00(2%)
105.78K to 103.93K
10-Jan-24 4:30 PM
View: 
Tahl Cindy
General Counsel and Secretary
Fate Therapeutics Inc (FATE) 09-Jan-24Sale 10,874$4.37$47,519.40(7%)
153.24K to 142.36K
10-Jan-24 4:29 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 09-Jan-24Sale 7,028$4.37$30,712.40(6%)
112.8K to 105.78K
10-Jan-24 4:29 PM
View: 
Wolchko J Scott
President and CEO
Director
Fate Therapeutics Inc (FATE) 09-Jan-24Sale 14,391$4.37$62,888.70(4%)
385.64K to 371.25K
10-Jan-24 4:30 PM
View: 
Valamehr Bahram
Chief R&D Officer
Fate Therapeutics Inc (FATE) 09-Jan-24Sale 11,271$4.38$49,367.00(7%)
169.34K to 158.07K
03-Jan-24 4:03 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 02-Jan-24Sale (Planned) 5,182$3.66$18,966.10(4%)
117.98K to 112.8K
28-Dec-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 26-Dec-23Disposition (other) 1,655,370$3.72$6,157,980.00(11%)
14.84M to 13.18M
28-Dec-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 26-Dec-23Purchase 44,630$3.72$166,024.00< 1%
14.79M to 14.84M
28-Dec-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 26-Dec-23Acquisition (other) 1,655,370$3.72$6,157,980.0013%
13.14M to 14.79M
19-Dec-23 4:01 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 18-Dec-23Sale (Planned) 1,585$3.50$5,547.50(1%)
119.57K to 117.98K
13-Nov-23 4:01 PM
View: 
Tahl Cindy
General Counsel and Secretary
Fate Therapeutics Inc (FATE) 09-Nov-23Sale (Planned) 24,363$2.40$58,471.20(14%)
177.6K to 153.24K
21-Aug-23 4:02 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 18-Aug-23Sale 4,718$2.80$13,210.40(4%)
124.29K to 119.57K
07-Aug-23 4:01 PM
View: 
Xu Yuan
Director
Fate Therapeutics Inc (FATE) 04-Aug-23Sale (Planned) 632$3.71$2,344.72(6%)
9.93K to 9.3K
06-Jul-23 5:19 PM
View: 
Powl Brian T.
Chief Commercial Officer
Fate Therapeutics Inc (FATE) 05-Jul-23Sale 3,854$4.87$18,769.00(9%)
45.0K to 41.15K
06-Jul-23 5:18 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 05-Jul-23Sale (Planned) 5,182$4.83$25,029.10(4%)
129.47K to 124.29K
15-Jun-23 4:05 PM
View: 
Xu Yuan
Director
Fate Therapeutics Inc (FATE) 14-Jun-23Sale (Planned) 3,460$5.58$19,306.80(26%)
13.39K to 9.93K
21-Apr-23 9:55 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 21-Apr-23Purchase 256,639$6.18$1,586,030.002%
12.88M to 13.14M
21-Apr-23 9:55 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 20-Apr-23Private Purchase 20,000$5.99$119,800.00< 1%
12.86M to 12.88M
19-Apr-23 4:07 PM
View: 
Chu Yu-Waye
Chief Medical Officer
Fate Therapeutics Inc (FATE) 18-Apr-23Sale 2,532$6.57$16,647.70(2%)
143.21K to 140.68K
17-Apr-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 14-Apr-23Disposition (other) 5,492,380$5.84$32,075,500.00(29%)
18.65M to 13.16M
17-Apr-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 14-Apr-23Purchase 25,700$6.00$154,200.00< 1%
18.63M to 18.65M
17-Apr-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 14-Apr-23Sale 302,339$5.84$1,765,660.00(2%)
13.16M to 12.86M
17-Apr-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 14-Apr-23Acquisition (other) 5,492,380$5.84$32,075,500.0042%
13.14M to 18.63M
17-Apr-23 9:30 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 13-Apr-23Conversion 167,205----1%
12.97M to 13.14M
20-Jan-23 4:14 PM
View: 
Mendlein John
Director
Fate Therapeutics Inc (FATE) 19-Jan-23Option Exercise 28,461$1.37$38,991.6010%
282.77K to 311.23K
13-Jan-23 6:20 PM
View: 
Mendlein John
Director
Fate Therapeutics Inc (FATE) 13-Jan-23Purchase 36,631$5.43$198,906.0015%
246.14K to 282.77K
13-Jan-23 4:02 PM
View: 
Valamehr Bahram
Chief R&D Officer
Fate Therapeutics Inc (FATE) 12-Jan-23Option Exercise 423$1.37$579.51< 1%
168.92K to 169.34K
13-Jan-23 6:20 PM
View: 
Mendlein John
Director
Fate Therapeutics Inc (FATE) 11-Jan-23Private Purchase 88,048$5.67$499,232.0056%
158.09K to 246.14K
11-Jan-23 4:05 PM
View: 
Chu Yu-Waye
Chief Medical Officer
Fate Therapeutics Inc (FATE) 10-Jan-23Sale 7,825$5.24$41,003.00(5%)
151.03K to 143.21K
11-Jan-23 4:07 PM
View: 
Plavsic Mark
Chief Technical Officer
Fate Therapeutics Inc (FATE) 10-Jan-23Sale 3,418$5.24$17,910.30(3%)
127.12K to 123.7K
11-Jan-23 4:09 PM
View: 
Wolchko J Scott
President and CEO
Director
Fate Therapeutics Inc (FATE) 10-Jan-23Sale 45,907$5.24$240,553.00(11%)
431.55K to 385.64K
11-Jan-23 4:08 PM
View: 
Valamehr Bahram
Chief R&D Officer
Fate Therapeutics Inc (FATE) 10-Jan-23Sale 10,917$5.24$57,205.10(6%)
179.83K to 168.92K
11-Jan-23 4:08 PM
View: 
Tahl Cindy
General Counsel and Secretary
Fate Therapeutics Inc (FATE) 10-Jan-23Sale 11,553$5.24$60,537.70(6%)
189.15K to 177.6K
11-Jan-23 4:06 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 10-Jan-23Sale 7,331$5.24$38,414.40(5%)
136.8K to 129.47K
19-Aug-22 6:58 PM
View: 
Dulac Edward J III
Chief Financial Officer
Fate Therapeutics Inc (FATE) 18-Aug-22Sale 5,135$29.81$153,051.00(4%)
141.94K to 136.8K
25-Jul-22 6:18 PM
View: 
Wolchko J Scott
President and CEO
Director
Fate Therapeutics Inc (FATE) 22-Jul-22Planned Option Sale 6,246$32.08$200,356.00(1%)
437.79K to 431.55K
25-Jul-22 6:18 PM
View: 
Wolchko J Scott
President and CEO
Director
Fate Therapeutics Inc (FATE) 22-Jul-22Option Exercise 6,246$2.70$16,864.201%
431.55K to 437.79K
25-Jul-22 6:18 PM
View: 
Wolchko J Scott
President and CEO
Director
Fate Therapeutics Inc (FATE) 21-Jul-22Option Exercise 30,000$2.70$81,000.007%
431.55K to 461.55K
25-Jul-22 6:18 PM
View: 
Wolchko J Scott
President and CEO
Director
Fate Therapeutics Inc (FATE) 21-Jul-22Planned Option Sale 30,000$32.88$986,361.00(6%)
461.55K to 431.55K
08-Jul-22 4:51 PM
View: 
Valamehr Bahram
Chief R&D Officer
Fate Therapeutics Inc (FATE) 07-Jul-22Option Exercise 17,158$2.73$46,841.3010%
179.83K to 196.99K
08-Jul-22 4:51 PM
View: 
Valamehr Bahram
Chief R&D Officer
Fate Therapeutics Inc (FATE) 07-Jul-22Planned Option Sale 17,158$30.23$518,686.00(9%)
196.99K to 179.83K
07-Jul-22 4:04 PM
View: 
Valamehr Bahram
Chief R&D Officer
Fate Therapeutics Inc (FATE) 06-Jul-22Option Exercise 7,842$3.27$25,628.704%
179.83K to 187.68K
07-Jul-22 4:04 PM
View: 
Valamehr Bahram
Chief R&D Officer
Fate Therapeutics Inc (FATE) 06-Jul-22Planned Option Sale 7,842$30.07$235,809.00(4%)
187.68K to 179.83K
06-Jul-22 4:04 PM
View: 
Plavsic Mark
Chief Technical Officer
Fate Therapeutics Inc (FATE) 05-Jul-22Sale 3,719$24.61$91,524.60(3%)
130.84K to 127.12K
29-Jun-22 5:02 PM
View: 
Powl Brian T.
Chief Commercial Officer
Fate Therapeutics Inc (FATE) 27-Jun-22Grant 45,000----100%
0 to 45.0K
13-Jun-22 9:30 PM
View: 
Lee Michael Stewart
Director
Fate Therapeutics Inc (FATE) 09-Jun-22Grant 8,650----323%
2.68K to 11.33K
13-Jun-22 9:31 PM
View: 
Redmile Group, LLC
Director
10% Owner
Fate Therapeutics Inc (FATE) 09-Jun-22Grant
Duplicate
8,650----< 1%
12.96M to 12.97M
13-Jun-22 4:43 PM
View: 
Rastetter William H
Director
Fate Therapeutics Inc (FATE) 09-Jun-22Grant 8,650----1%
608.77K to 617.42K
13-Jun-22 4:41 PM
View: 
Jooss Karin
Director
Fate Therapeutics Inc (FATE) 09-Jun-22Grant 8,650----722%
1.2K to 9.85K